BETAHISTINE TABLET

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

BETAHISTINE HYDROCHLORIDE

Disponible depuis:

SANIS HEALTH INC

Code ATC:

N07CA01

DCI (Dénomination commune internationale):

BETAHISTINE

Dosage:

24MG

forme pharmaceutique:

TABLET

Composition:

BETAHISTINE HYDROCHLORIDE 24MG

Mode d'administration:

ORAL

Unités en paquet:

100

Type d'ordonnance:

Prescription

Domaine thérapeutique:

MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS

Descriptif du produit:

Active ingredient group (AIG) number: 0103555004; AHFS:

Statut de autorisation:

APPROVED

Date de l'autorisation:

2022-02-08

Notice patient

IMPORTANT: PLEASE READ
_BETAHISTINE Product Monograph _
_Page 19 of 20_
PART III: CONSUMER INFORMATION
Pr
BETAHISTINE
BETAHISTINE DIHYDROCHLORIDE TABLETS, HOUSE STANDARD
READ THIS CAREFULLY BEFORE YOU START TAKING BETAHISTINE
AND EACH TIME YOU GET A REFILL. THIS LEAFLET IS A SUMMARY AND
WILL NOT TELL YOU EVERYTHING ABOUT BETAHISTINE. TALK TO
YOUR DOCTOR, NURSE, OR PHARMACIST ABOUT YOUR MEDICAL
CONDITION AND TREATMENT AND ASK IF THERE IS ANY NEW
INFORMATION ABOUT BETAHISTINE.
ABOUT THIS MEDICATION
WHAT THE MEDICATION IS USED FOR:
BETAHISTINE is used for reducing the episodes of recurrent
vertigo (dizziness) associated with Ménière’s disease.
WHAT IT DOES:
BETAHISTINE is a type of medicine called a histamine-
analogue. It is thought to work by helping the blood flow in your
inner ear, which lowers the build up of pressure. It is this build
up of pressure in the ear which is thought to cause feelings of
dizziness (vertigo), feelings of being sick (nausea and vomiting),
ringing in the ears (tinnitus), and hearing loss or hearing
difficulty suffered by people with Ménière’s disease.
WHEN IT SHOULD NOT BE USED:
Do not use BETAHISTINE if:

you are allergic (hypersensitive) to betahistine
dihydrochloride or to any of the non-medicinal ingredients
in the product.

you have a peptic (stomach) ulcer or have a history of this
condition.

your doctor has told you that you have an adrenal gland
tumour (called pheochromocytoma).
WHAT THE MEDICINAL INGREDIENT IS:
Betahistine dihydrochloride
WHAT THE NON-MEDICINAL INGREDIENTS ARE:
Colloidal Anhydrous Silica, Crospovidone, Lactose
Monohydrate, Microcrystalline Cellulose, Povidone and Stearic
Acid
WHAT DOSAGE FORMS IT COMES IN:
Tablets: 16 mg and 24 mg.
WARNINGS AND PRECAUTIONS
BEFORE YOU USE BETAHISTINE TALK TO YOUR DOCTOR, NURSE
OR PHARMACIST IF YOU:

have or have had health problems in the past.

you are taking medications, including ones you can take
without a doctor’s prescription e.g., natural or herbal
remedies.

suffer from bronchial asthma, sinc

Résumé des caractéristiques du produit

PRODUCT MONOGRAPH
PR BETAHISTINE
Betahistine Dihydrochloride Tablets
8 MG, 16 MG AND 24 MG
Manufacturer’s standard
ANTI-VERTIGO AGENT
Sanis Health Inc.
1 President's Choice Circle
Brampton, Ontario
L6Y 5S5
Control Number: 260285
Date of
Preparation:
February 8, 2022
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
4
DRUG INTERACTIONS
...................................................................................................
6
DOSAGE AND ADMINISTRATION
...............................................................................
6
OVERDOSAGE
.................................................................................................................
7
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 7
STORAGE AND STABILITY
.........................................................................................
10
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 10
PART II: SCIENTIFIC INFORMATION
..............................................................................
11
PHARMACEUTICAL INFORMATION
.........................................................................
11
CLINICAL TRIALS
.........................................................................................................
12
DETAILED PHARMACOLOGY
.................................................................................